Kiniksa Pharmaceuticals International, plc
KNSA
$47.02
$0.521.12%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 11.76% | 15.34% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.76% | 15.34% | |||
| Cost of Revenue | 8.87% | 17.66% | |||
| Gross Profit | 14.25% | 13.42% | |||
| SG&A Expenses | 15.62% | 4.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.28% | 14.78% | |||
| Operating Income | -17.71% | 19.15% | |||
| Income Before Tax | -14.32% | 18.71% | |||
| Income Tax Expenses | 3.99% | 72.88% | |||
| Earnings from Continuing Operations | -22.98% | 3.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -22.98% | 3.38% | |||
| EBIT | -17.71% | 19.15% | |||
| EBITDA | -17.09% | 18.94% | |||
| EPS Basic | -24.24% | 1.61% | |||
| Normalized Basic EPS | -15.76% | 16.69% | |||
| EPS Diluted | -21.61% | 0.00% | |||
| Normalized Diluted EPS | -16.22% | 15.65% | |||
| Average Basic Shares Outstanding | 1.70% | 1.74% | |||
| Average Diluted Shares Outstanding | 2.25% | 2.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||